GSK, Dr. Reddy’s to collaborate on branded drugs
LONDON One of the world’s largest pharmaceutical companies and a drug maker focused on generics plan to collaborate to drive sales growth in developing countries.
United Kingdom-based GlaxoSmithKline and India-based Dr. Reddy’s Labs announced Monday an agreement to develop and market Dr. Reddy’s branded drugs in several emerging markets.
“This is another significant step forward in our strategy to grow and diversify GSK’s business in emerging markets,” GSK president for emerging markets Abbas Hussain stated. “Growth in both population and economic prosperity is leading to increased demand for branded pharmaceuticals.”
Under the terms of the agreement, which took effect Monday, GSK will gain exclusive access to Dr. Reddy’s portfolio and pipeline of more than 100 branded drugs and market them in Africa, the Middle East, the Asia Pacific region and Latin America.
“We are extremely pleased to combine forces with GSK, a global leader, to fully realize the potential of our strengths in technology, product development and manufacturing across a range of high-growth emerging markets,” Dr. Reddy’s CEO and vice chairman G.V. Prasad said.
Maryland offers free prescription card to residents
ANNAPOLIS, Md. Maryland earlier this week launched a new statewide discount drug card program, called the Maryland Rx Card. The program, free to all Maryland residents, will provide savings of up to 75% on prescription drugs, though savings should average roughly 30%.
The program has no restrictions to membership, including no income requirements and no age limitations, and will be accepted at more than 50,000 pharmacy locations across the country.
Novo Nordisk discusses diabetes costs, patient motivation at conference
WASHINGTON The cost of diabetes to the country and the lag in patient motivation to take action to offset it were the major themes at a conference sponsored recently by a drug maker focused on the disease.
Danish drug maker Novo Nordisk convened the conference in Washington, bringing in such speakers as American Diabetes Association CEO Larry Hausner.
Without intervention at the national and patient level, the company said, the country runs the risk of having 50 million people living with the disease by 2025.
“The growing prevalence of diabetes is having a profound effect on the health of current and future generations, as well as our national economy,” Hausner said. “We must awaken the public’s consciousness of diabetes and ensure our leaders in Congress recognize healthcare reform as their opportunity to transform the lives of all people affected by this devastating disease.”